SI-BONE (SIBN) Set to Announce Earnings on Monday

SI-BONE (NASDAQ:SIBNGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, August 8th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. SI-BONE has set its FY 2022 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

SI-BONE (NASDAQ:SIBNGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09). The firm had revenue of $22.44 million during the quarter, compared to analysts’ expectations of $22.37 million. SI-BONE had a negative net margin of 67.00% and a negative return on equity of 44.52%. During the same quarter last year, the company posted ($0.37) EPS. On average, analysts expect SI-BONE to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SI-BONE Stock Up 0.7 %

Shares of NASDAQ:SIBN opened at $16.69 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.48 and a current ratio of 10.44. The company has a market cap of $565.52 million, a PE ratio of -9.02 and a beta of 1.35. SI-BONE has a 52 week low of $11.89 and a 52 week high of $25.96. The firm has a 50 day simple moving average of $14.02 and a 200 day simple moving average of $17.53.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their target price on shares of SI-BONE from $32.00 to $25.00 in a research report on Tuesday, May 10th. JMP Securities reiterated a “buy” rating and issued a $36.00 target price on shares of SI-BONE in a research report on Wednesday, June 1st. Morgan Stanley dropped their price target on shares of SI-BONE from $22.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, July 15th. Finally, Truist Financial dropped their price target on shares of SI-BONE to $17.00 in a research note on Friday, July 22nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $28.29.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 5,466 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $12.58, for a total value of $68,762.28. Following the transaction, the insider now directly owns 174,386 shares in the company, valued at approximately $2,193,775.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Anthony J. Recupero sold 5,466 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $12.58, for a total value of $68,762.28. Following the transaction, the insider now directly owns 174,386 shares in the company, valued at approximately $2,193,775.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Anshul Maheshwari sold 4,111 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $12.58, for a total transaction of $51,716.38. Following the completion of the transaction, the chief financial officer now owns 90,748 shares in the company, valued at $1,141,609.84. The disclosure for this sale can be found here. Insiders have sold a total of 28,439 shares of company stock worth $365,329 in the last 90 days. 5.40% of the stock is owned by insiders.

Institutional Trading of SI-BONE

A number of hedge funds have recently bought and sold shares of SIBN. JPMorgan Chase & Co. boosted its holdings in SI-BONE by 37.9% in the 1st quarter. JPMorgan Chase & Co. now owns 167,745 shares of the company’s stock valued at $3,791,000 after purchasing an additional 46,086 shares during the period. HighTower Advisors LLC bought a new stake in SI-BONE in the 1st quarter valued at $220,000. MetLife Investment Management LLC boosted its holdings in SI-BONE by 54.2% in the 1st quarter. MetLife Investment Management LLC now owns 18,825 shares of the company’s stock valued at $425,000 after purchasing an additional 6,615 shares during the period. Rhumbline Advisers lifted its holdings in shares of SI-BONE by 8.3% during the 1st quarter. Rhumbline Advisers now owns 32,233 shares of the company’s stock worth $728,000 after acquiring an additional 2,476 shares during the period. Finally, BlackRock Inc. lifted its holdings in shares of SI-BONE by 0.4% during the 1st quarter. BlackRock Inc. now owns 2,709,443 shares of the company’s stock worth $61,233,000 after acquiring an additional 9,645 shares during the period. 99.36% of the stock is owned by institutional investors.

About SI-BONE

(Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Featured Stories

Earnings History for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.